The basis for immunotherapy in multiple myeloma

Ignacio Melero Bermejo, MD, from the University Clinic of Navarra, Pamplona, Spain provides the highlights from his talk on the basis for immunotherapy in multiple myeloma (MM) at the 2016 European Multiple Myeloma Academy (EMMA) in Madrid, Spain. Dr Melero Bermejo outlines his talk starting with the main mechanism of action for the new immunotherapies developed for MM (for example elotuzumab and dacetuzumab), including antibody-dependent cellular cytotoxicity. Next, Dr Melero Bermejo discusses data he presented on the implementation of immunomodulation, showing its mechanism of action and the effect seen in solid tumors in combination with checkpoint inhibitors. He goes on to talk about the latest data on PD-1 antibodies in combination with thalidomide analogues in MM. Dr Melero Bermejo reviews adoptive T-cell transfer, using CAR-transduced T-cells, which is new potential therapy regime for MM.
This programme has been supported by Celgene and Amgen through an unrestricted educational grant to the Video Journal of Hematological Oncology.

Share this video